CERS

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Bjerkholt EricDirector --282.1k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --
Gregory Dean A.Director --146.7k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --
Lucena AnnDirector --232.3k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --
Nachtsheim Jami KDirector --268.4k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --
Shan HuaDirector --192.4k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --
Witney FrankDirector --340.1k shares Grant / ExerciseJun 2, 2026 Disclosure amount unavailable60k shares -- --

News

businesswire.comCerus Corporation Closes New Debt Facility of Up to $110 Millionbusinesswire.comJun 8

businesswire.comBradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucenabusinesswire.comMay 27

seekingalpha.comCerus Corporation: Strong Q1 Results Validate The Turnaround Thesisseekingalpha.comMay 10

seekingalpha.comCerus Corporation (CERS) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 1

businesswire.comCerus Corporation Announces First Quarter 2026 Financial Resultsbusinesswire.comApr 30

Trade CERS

About Cerus Corporation

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

CEO: William Greenman
IPO Date: Jan 31, 1997

Market Data

Open: $2.59
High: $2.64
Low: $2.56
Volume: 597.3K
52W High: $3.15
52W Low: $1.15

Valuation

Market Cap: $515M
Enterprise Value: $584M

Financials

Free Cash Flow: $8.5M
Revenue: $206M
Net Income: $-16M
Cash: $20M
Debt: $97M

Events

EarningsAug 4

EPS est. -0.01333